Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XL092 |
| Synonyms | |
| Therapy Description |
XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XL092 | XL-092|XL 092|Zanzalintinib | MET Inhibitor 59 VEGFR Inhibitor (Pan) 36 | XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 0 |
| NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
| NCT06568562 | Phase II | XL092 | XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer (PRO-XL) | Not yet recruiting | USA | 0 |
| NCT06571734 | Phase II | XL092 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma | Recruiting | USA | 0 |
CKB BOOST